• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial
This study aimed to compare the immunogenicity of the E coli-produced HPV 9-valent vaccine Cecolin 9 (against HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58) with Gardasil 9.METHODS: This was a randomised, single-blind trial conducted in China. Healthy non-pregnant women aged 18-26 years, who were not breastfeeding and with no HPV vaccination history, were enrolled in the Ganyu Centre for Disease Control and Prevention (Lianyungang City, Jiangsu Province, China). Women were stratified by age (18-22 years and 23-26 years) and randomly assigned (1:1) using a permutated block size of eight to receive three doses of Cecolin 9 or Ga...
Source: Cancer Control - July 20, 2023 Category: Cancer & Oncology Authors: Feng-Cai Zhu Guo-Hua Zhong Wei-Jin Huang Kai Chu Li Zhang Zhao-Feng Bi Kong-Xin Zhu Qi Chen Ting-Quan Zheng Ming-Lei Zhang Sheng Liu Jin-Bo Xu Hong-Xing Pan Guang Sun Feng-Zhu Zheng Qiu-Fen Zhang Xiu-Mei Yi Si-Jie Zhuang Shou-Jie Huang Hui-Rong Pan Ying-Y Source Type: research

Nationwide introduction of HPV vaccine in Zimbabwe 2018-2019: Experiences with multiple cohort vaccination delivery
PLOS Glob Public Health. 2022 Apr 6;2(4):e0000101. doi: 10.1371/journal.pgph.0000101. eCollection 2022.ABSTRACTThe World Health Organization (WHO) recommends the human papillomavirus (HPV) vaccine for girls aged 9-14 years for cervical cancer prevention and encourages vaccinating multiple cohorts in the first year to maximize impact. The HPV vaccine was introduced nationwide in Zimbabwe in 2018 through a 1-week school-based campaign to multiple cohorts (all girls 10-14 years old), followed by a single cohort (grade 5 girls in school and age 10 girls out-of-school) in 2019. During the 2019 campaign, the multiple cohort's se...
Source: Cancer Control - March 24, 2023 Category: Cancer & Oncology Authors: Julie Garon Carlton Joan Marembo Portia Manangazira Maxwell Rupfutse Adelaide Shearley Egnes Makwabarara Anna Hidle Anagha Loharikar Source Type: research

Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial
Lancet Oncol. 2022 Jun 13:S1470-2045(22)00291-1. doi: 10.1016/S1470-2045(22)00291-1. Online ahead of print.ABSTRACTBACKGROUND: In women vaccinated against human papillomavirus (HPV), reductions in cervical disease and related procedures results in more women having intact transformation zones, potentially increasing the risk of cervical lesions caused by non-vaccine-preventable HPV types, a phenomenon termed clinical unmasking. We aimed to evaluate HPV vaccine efficacy against cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and cervical intraepithelial neoplasia grade 3 or worse (CIN3+) attributed to non-preven...
Source: Cancer Control - June 16, 2022 Category: Cancer & Oncology Authors: Jaimie Z Shing Shangying Hu Rolando Herrero Allan Hildesheim Carolina Porras Joshua N Sampson John Schussler John T Schiller Douglas R Lowy M ónica S Sierra Loretto Carvajal Aim ée R Kreimer Costa Rica HPV Vaccine Trial Group Source Type: research

Immunotherapy for the treatment of penile intraepithelial neoplasia associated with human papilloma virus type 16 using topical imiquimod and human papilloma virus vaccination
Australas J Dermatol. 2021 Aug 31. doi: 10.1111/ajd.13709. Online ahead of print.ABSTRACTPenile intraepithelial neoplasia (PeIN) is frequently associated with human papilloma virus (HPV). Three cases of PeIN associated with HPV-type 16 were successfully treated with topical imiquimod and concurrent HPV vaccination. Human papilloma vaccine protects against oncogenic human papilloma viruses. In New Zealand, a decline in incidence of PeIN is anticipated with the recent funding of human papilloma vaccine for boys and young men aged 9-26 years. Therefore, HPV vaccination may have a role for treatment of PeIN and prophylaxis.PMI...
Source: The Australasian Journal of Dermatology - August 31, 2021 Category: Dermatology Authors: Tae Yeb Kim Moushumi Das Natalie Poppito Paul Jarrett Source Type: research

IFIT5 Participates in the Antiviral Mechanisms of Rainbow Trout Red Blood Cells
We described a new defense mechanism based on IFIT5 antiviral activity in nucleated RBCs that appeared to contribute to halting the VHSV infection. This finding sheds light into novel antiviral therapeutics to mitigate the economic losses and social impact caused by viral infections in the aquaculture industry. This work broadens the knowledge of fish nucleated RBCs functions and their role in the immune response to viral infections. Ethics Statement Experimental protocols and methods relating to experimental animals were reviewed and approved by the Animal Welfare Body and the Research Ethics Committee at the University...
Source: Frontiers in Immunology - April 15, 2019 Category: Allergy & Immunology Source Type: research